JP2014520838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520838A5 JP2014520838A5 JP2014519625A JP2014519625A JP2014520838A5 JP 2014520838 A5 JP2014520838 A5 JP 2014520838A5 JP 2014519625 A JP2014519625 A JP 2014519625A JP 2014519625 A JP2014519625 A JP 2014519625A JP 2014520838 A5 JP2014520838 A5 JP 2014520838A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- cox
- crystalline form
- tnf
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- -1 phenylbutazone) Chemical class 0.000 description 2
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N AZAPROPAZONE Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 229940091143 Apazone Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 229960005207 Auranofin Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 229940111134 Coxibs Drugs 0.000 description 1
- 229940073621 Enbrel Drugs 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229940111120 Gold preparations Drugs 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 Hydroxychloroquine Drugs 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229940116176 Remicade Drugs 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229960001940 Sulfasalazine Drugs 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940051880 analgesics and antipyretics Pyrazolones Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940111136 antiinflammatory and antirheumatic drugs Fenamates Drugs 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
Description
さらなる面において形態Ａは、Ｘ線１.５４１８Åの波長を使用して測定して、８.５、９.７、１０.６、１７.１、１９.９および２１.２の２シータ(度)で特徴的ピークを有するＸ線粉末回折パターンを有する。
当業者には認識され得るとおり、得られる結晶形態は、結晶化工程の動力学および熱力学の両者に依存する。ある熱力学的条件下(溶媒系、温度、圧力および本発明の化合物の濃度)、一つの結晶形態は他の一つ(または実際他のすべて)より安定であり得る。しかしながら、比較すると、相対的に低い熱力学的安定性を有し得る他の結晶形態が、動力学的に好ましいことがある。故に、さらに、動力学的因子、例えば時間、不純物プロファイル、撹拌、種晶の存在なども、その形態が出現するかに影響し得る。故に、ここに記載する方法は、特定の結晶形態の式(Ｉ)の化合物を得るために適宜当業者により改良され得る。
特に、炎症性疾患リウマチ性関節炎、乾癬、炎症性腸疾患、過敏性腸症候群、ＣＯＰＤ、喘息およびアレルギー性鼻炎の処置のために、本発明の化合物はＴＮＦ−α阻害剤、例えば抗ＴＮＦモノクローナル抗体(例えばレミケード、CDP-870およびD2.E7.)およびＴＮＦ受容体免疫グロブリン分子、例えばエタネルセプト(Enbrel)、非選択的ＣＯＸ−１／ＣＯＸ−２阻害剤(例えばピロキシカム、ジクロフェナク)、プロピオン酸類、例えばナプロキセン、フルルビプロフェン、フェノプロフェン、ケトプロフェンおよびイブプロフェン)、フェナメート(例えばメフェナム酸、インドメタシン、スリンダク、アパゾン)、ピラゾロン類(例えばフェニルブタゾン)、サリチレート(例えばアスピリン)、ＣＯＸ−２阻害剤(例えばメロキシカム、セレコキシブ、ロフェコキシブ、バルデコキシブおよびエトリコキシブ)、低用量メトトレキサート、レフノミド；シクレソニド；ヒドロキシクロロキン、ｄ−ペニシラミン、オーラノフィンまたは非経腸または経口金製剤のような薬剤と組み合わせ得る。炎症性腸疾患および過敏性腸障害に対して、さらに好都合な薬剤はスルファサラジンおよび５−ＡＳＡ類、局所および全身ステロイド類、免疫調節剤および免疫抑制剤、抗生物質、プロバイオティクスおよび抗インテグリン類を含む。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161506737P | 2011-07-12 | 2011-07-12 | |
| US61/506,737 | 2011-07-12 | ||
| PCT/GB2012/051620 WO2013008002A1 (en) | 2011-07-12 | 2012-07-10 | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016131785A Division JP6261666B2 (ja) | 2011-07-12 | 2016-07-01 | ケモカイン受容体モジュレーターとしてのｎ−（６−（（２ｒ，３ｓ）−３，４−ジヒドロキシブタン−２−イルオキシ）−２−（４−フルオロベンジルチオ）ピリミジン−４−イル）−３−メチルアゼチジン−１−スルホンアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520838A JP2014520838A (ja) | 2014-08-25 |
| JP2014520838A5 true JP2014520838A5 (ja) | 2015-08-20 |
| JP6006308B2 JP6006308B2 (ja) | 2016-10-12 |
Family
ID=46513787
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519625A Active JP6006308B2 (ja) | 2011-07-12 | 2012-07-10 | ケモカイン受容体モジュレーターとしてのｎ−（６−（（２ｒ，３ｓ）−３，４−ジヒドロキシブタン−２−イルオキシ）−２−（４−フルオロベンジルチオ）ピリミジン−４−イル）−３−メチルアゼチジン−１−スルホンアミド |
| JP2016131785A Active JP6261666B2 (ja) | 2011-07-12 | 2016-07-01 | ケモカイン受容体モジュレーターとしてのｎ−（６−（（２ｒ，３ｓ）−３，４−ジヒドロキシブタン−２−イルオキシ）−２−（４−フルオロベンジルチオ）ピリミジン−４−イル）−３−メチルアゼチジン−１−スルホンアミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016131785A Active JP6261666B2 (ja) | 2011-07-12 | 2016-07-01 | ケモカイン受容体モジュレーターとしてのｎ−（６−（（２ｒ，３ｓ）−３，４−ジヒドロキシブタン−２−イルオキシ）−２−（４−フルオロベンジルチオ）ピリミジン−４−イル）−３−メチルアゼチジン−１−スルホンアミド |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US8735413B2 (ja) |
| EP (2) | EP3255043B1 (ja) |
| JP (2) | JP6006308B2 (ja) |
| KR (1) | KR101946664B1 (ja) |
| CN (1) | CN103781781B (ja) |
| AR (2) | AR087168A1 (ja) |
| AU (2) | AU2012282316B2 (ja) |
| BR (1) | BR112014000636B1 (ja) |
| CA (1) | CA2841859C (ja) |
| CL (1) | CL2014000079A1 (ja) |
| CO (1) | CO6852072A2 (ja) |
| CR (1) | CR20140007A (ja) |
| CU (2) | CU24292B1 (ja) |
| CY (1) | CY1124329T1 (ja) |
| DK (1) | DK3255043T3 (ja) |
| DO (1) | DOP2013000308A (ja) |
| EA (1) | EA027821B1 (ja) |
| EC (1) | ECSP14013130A (ja) |
| ES (1) | ES2861927T3 (ja) |
| HK (1) | HK1245779A1 (ja) |
| HR (1) | HRP20210413T1 (ja) |
| HU (1) | HUE053703T2 (ja) |
| IL (1) | IL230398A (ja) |
| LT (1) | LT3255043T (ja) |
| MX (2) | MX342874B (ja) |
| MY (1) | MY180039A (ja) |
| NI (1) | NI201400002A (ja) |
| PE (2) | PE20141944A1 (ja) |
| PL (1) | PL3255043T3 (ja) |
| PT (1) | PT3255043T (ja) |
| RS (1) | RS61608B1 (ja) |
| SG (1) | SG10201605619XA (ja) |
| SI (1) | SI3255043T1 (ja) |
| TW (2) | TWI659026B (ja) |
| UY (1) | UY34191A (ja) |
| WO (1) | WO2013008002A1 (ja) |
| ZA (1) | ZA201401059B (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013000289A (es) | 2010-07-13 | 2013-03-08 | Astrazeneca Ab | Nuevas formas cristalinas de n-[2-[[(2,3-difluorofenil)metil]tio]- 6-{[(1r, 2s)-2,3-dihidroxi-1-metilpropil]oxi}-4-pirimidinil]-1-aze tidinsulfonamida. |
| SI3255043T1 (sl) * | 2011-07-12 | 2021-04-30 | Astrazeneca Ab | N-(6-((2R,3S)-3,4-dihidroksibutan-2-iloksi)-2-(4-fluorobenziltio) pirimidin-4-il)-3-metilazetidin-1-sulfonamid, kot modulator kemokinskega receptorja |
| EP3141235A1 (en) * | 2012-12-06 | 2017-03-15 | IP Gesellschaft für Management mbH | N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide |
| JP6883917B2 (ja) * | 2016-03-11 | 2021-06-09 | アルデア バイオサイエンシーズ インク． | 結晶性関節障害を処置するためのｃｘｃｒ−２阻害剤 |
| CN111356675A (zh) * | 2017-09-12 | 2020-06-30 | 阿迪亚生命科学公司 | 用于治疗病症的cxcr-2抑制剂 |
| JP7336541B2 (ja) | 2019-06-12 | 2023-08-31 | ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ | 過酸化ジアシルを生成するためのプロセス |
| BR112021024870A2 (pt) * | 2019-06-12 | 2022-01-18 | Nouryon Chemicals Int Bv | Método para isolar ácido carboxílico de uma corrente lateral aquosa de um processo de produção de peróxido orgânico |
| US11976034B2 (en) | 2019-06-12 | 2024-05-07 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3457278A (en) * | 1964-10-15 | 1969-07-22 | Geigy Chem Corp | Cyclopropyl-4-sulfanilamido-pyrimidines |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| FI981521A0 (fi) * | 1998-07-01 | 1998-07-01 | Orion Corp | Substituoidut beta-diketonit ja niiden käyttö |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| GB0419235D0 (en) * | 2004-08-28 | 2004-09-29 | Astrazeneca Ab | Compounds |
| ES2442678T3 (es) | 2004-08-28 | 2014-02-12 | Astrazeneca Ab | Derivados de pirimidín sulfonamidas como moduladores del receptor de quimioquina |
| ES2600804T3 (es) * | 2006-01-19 | 2017-02-10 | Orchid Pharma Limited | Nuevos heterociclos |
| WO2008157273A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
| TW201006824A (en) * | 2008-07-16 | 2010-02-16 | Astrazeneca Ab | Novel compound 395 |
| EP2310354A2 (de) | 2008-07-25 | 2011-04-20 | Basf Se | 3-aminomethyl-1-cyclohexylamin und ein verfahren zu dessen herstellung |
| MX2013000289A (es) * | 2010-07-13 | 2013-03-08 | Astrazeneca Ab | Nuevas formas cristalinas de n-[2-[[(2,3-difluorofenil)metil]tio]- 6-{[(1r, 2s)-2,3-dihidroxi-1-metilpropil]oxi}-4-pirimidinil]-1-aze tidinsulfonamida. |
| SI3255043T1 (sl) * | 2011-07-12 | 2021-04-30 | Astrazeneca Ab | N-(6-((2R,3S)-3,4-dihidroksibutan-2-iloksi)-2-(4-fluorobenziltio) pirimidin-4-il)-3-metilazetidin-1-sulfonamid, kot modulator kemokinskega receptorja |
-
2012
- 2012-07-10 SI SI201231899T patent/SI3255043T1/sl unknown
- 2012-07-10 PE PE2014000009A patent/PE20141944A1/es active IP Right Grant
- 2012-07-10 JP JP2014519625A patent/JP6006308B2/ja active Active
- 2012-07-10 BR BR112014000636-9A patent/BR112014000636B1/pt not_active IP Right Cessation
- 2012-07-10 CN CN201280044385.0A patent/CN103781781B/zh active Active
- 2012-07-10 MX MX2013015085A patent/MX342874B/es active IP Right Grant
- 2012-07-10 AU AU2012282316A patent/AU2012282316B2/en not_active Ceased
- 2012-07-10 WO PCT/GB2012/051620 patent/WO2013008002A1/en active Application Filing
- 2012-07-10 EA EA201490077A patent/EA027821B1/ru not_active IP Right Cessation
- 2012-07-10 MX MX2016000277A patent/MX353334B/es unknown
- 2012-07-10 DK DK16202983.9T patent/DK3255043T3/da active
- 2012-07-10 PT PT162029839T patent/PT3255043T/pt unknown
- 2012-07-10 MY MYPI2014700061A patent/MY180039A/en unknown
- 2012-07-10 CA CA2841859A patent/CA2841859C/en active Active
- 2012-07-10 RS RS20210370A patent/RS61608B1/sr unknown
- 2012-07-10 CU CUP2014000004A patent/CU24292B1/xx unknown
- 2012-07-10 LT LTEP16202983.9T patent/LT3255043T/lt unknown
- 2012-07-10 KR KR1020147000487A patent/KR101946664B1/ko active IP Right Grant
- 2012-07-10 PE PE2018000520A patent/PE20181069A1/es unknown
- 2012-07-10 ES ES16202983T patent/ES2861927T3/es active Active
- 2012-07-10 SG SG10201605619XA patent/SG10201605619XA/en unknown
- 2012-07-10 EP EP16202983.9A patent/EP3255043B1/en active Active
- 2012-07-10 PL PL16202983T patent/PL3255043T3/pl unknown
- 2012-07-10 EP EP12735323.3A patent/EP2731945A1/en not_active Withdrawn
- 2012-07-10 HU HUE16202983A patent/HUE053703T2/hu unknown
- 2012-07-11 TW TW106135796A patent/TWI659026B/zh not_active IP Right Cessation
- 2012-07-11 UY UY0001034191A patent/UY34191A/es not_active Application Discontinuation
- 2012-07-11 TW TW101124908A patent/TWI633098B/zh active
- 2012-07-11 US US13/546,444 patent/US8735413B2/en active Active
- 2012-07-12 AR ARP120102531A patent/AR087168A1/es not_active Application Discontinuation
-
2013
- 2013-12-17 DO DO2013000308A patent/DOP2013000308A/es unknown
-
2014
- 2014-01-09 NI NI201400002A patent/NI201400002A/es unknown
- 2014-01-09 IL IL230398A patent/IL230398A/en active IP Right Grant
- 2014-01-09 CR CR20140007A patent/CR20140007A/es unknown
- 2014-01-10 CO CO14004182A patent/CO6852072A2/es active IP Right Grant
- 2014-01-10 CL CL2014000079A patent/CL2014000079A1/es unknown
- 2014-01-10 EC ECSP14013130 patent/ECSP14013130A/es unknown
- 2014-02-11 ZA ZA2014/01059A patent/ZA201401059B/en unknown
- 2014-04-15 US US14/253,288 patent/US9221782B2/en not_active Expired - Fee Related
- 2014-11-03 HK HK18105226.5A patent/HK1245779A1/zh unknown
-
2015
- 2015-12-28 US US14/980,754 patent/US9975881B2/en active Active
-
2016
- 2016-06-10 CU CUP2016000083A patent/CU20160083A7/es unknown
- 2016-07-01 JP JP2016131785A patent/JP6261666B2/ja active Active
- 2016-10-12 AU AU2016244246A patent/AU2016244246B2/en not_active Ceased
-
2021
- 2021-03-12 HR HRP20210413TT patent/HRP20210413T1/hr unknown
- 2021-04-07 CY CY20211100296T patent/CY1124329T1/el unknown
-
2022
- 2022-01-21 AR ARP220100128A patent/AR124688A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520838A5 (ja) | ||
| HRP20210388T1 (hr) | Kristalni polimorf slobodne baze od 2-hidroksi-6-((2-(1-izopropil-1h-pirazol-5-il)piridin-3-il)metoksi)benzaldehida | |
| JP2008505054A5 (ja) | ||
| KR102134171B1 (ko) | 란티오닌 합성효소 c-유사 2-계 치료제 | |
| JP2017222697A5 (ja) | ||
| AU2016219612A1 (en) | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | |
| EA201400056A1 (ru) | Вещества, связывающие ядерные рецепторы | |
| JP2010519260A5 (ja) | ||
| JP2011516433A5 (ja) | ||
| JP2013541600A5 (ja) | ||
| HRP20171763T1 (hr) | Derivati piridin-4-ila | |
| MX366293B (es) | Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal. | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| JP2012512814A5 (ja) | ||
| Quattrocchi et al. | The role of anti-nucleosome antibodies in systemic lupus erythematosus. Results of a study of patients with systemic lupus erythematosus and other connective tissue diseases | |
| JP2016520556A5 (ja) | ||
| Alinda et al. | Nucleation of supersaturated flufenamic acid cocrystal solutions in the presence of a polymer | |
| RU2017142996A (ru) | Натриевая соль ингибитора транспортера мочевой кислоты и его кристаллическая форма | |
| CN104356073B (zh) | 一种微波辅助高效合成5-氰尿嘧啶的方法 | |
| Smith et al. | Fetuin-A in the peritoneal effluent of patients with encapsulating peritoneal sclerosis—more than a protein? | |
| Ghodsi et al. | 2-Aryl quinolines related to some nsaids are selective COX-2 inhibitors | |
| Dumusc et al. | Spondyloarthropathies: traitements conventionnels et anti-TNF | |
| JP2017095442A5 (ja) | ||
| Karmova et al. | Synthesis of Chlorin-Fullerene Conjugate | |
| Liu et al. | CLL Stereotyped Subset# 4 Igs Acquire Binding to Viable B Lymphocyte Surfaces By Somatic Mutations, Isotype Class Switching, and with the Prerequisite of IG Self-Association |